ArticleFrontiers in oncology2017
"Targeted" Chemotherapy for Esophageal Cancer.
Article in Frontiers in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- YAP as a therapeutic target in esophageal squamous cell carcinoma: insights and strategies.Annals of medicine · 2025Review
- Global trends in esophageal cancer: sex and age disparities in health inequalities from 1990 to 2021, with projections to 2050.Frontiers in oncology · 2025Article
- The Evolving Paradigm of Esophageal and Esophagogastric Junction Adenocarcinoma: Current Insights, Emerging Therapies, and Future Directions.Journal of cancer science and clinical therapeutics · 2025Article
- Article
- Paclitaxel promotes mTOR signaling-mediated apoptosis in esophageal cancer cells by targeting MUC20.Thoracic cancer · 2023Article
- Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review.Current oncology (Toronto, Ont.) · 2023Review
- Toosendanin targeting eEF2 impedes Topoisomerase I & II protein translation to suppress esophageal squamous cell carcinoma growth.Journal of experimental & clinical cancer research : CR · 2023Article
- The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett's Neoplasia.Gastroenterology · 2022Article
- Alpha Protein Kinase 2 Promotes Esophageal Cancer via Integrin Alpha 11.BioMed research international · 2022Article
- Identification of Candidate Therapeutic Genes for More Precise Treatment of Esophageal Squamous Cell Carcinoma and Adenocarcinoma.Frontiers in genetics · 2022Article
- Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review.Journal of gastrointestinal oncology · 2021Review
- Article
- Advances in targeted therapy for esophageal cancer.Signal transduction and targeted therapy · 2020Review
- Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.Scientific reports · 2020Article
- Allelic Imbalance Analysis in Liquid Biopsy to Monitor Locally Advanced Esophageal Cancer Patients During Treatment.Frontiers in oncology · 2020Article
- Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers.Medical sciences (Basel, Switzerland) · 2019Review
- Discovery of Novel and Clinically Relevant Markers in Formalin-Fixed Paraffin-Embedded Esophageal Cancer Specimen.Frontiers in oncology · 2018Article
- Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes.Frontiers in oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.